TG Therapeutics, Inc. (TGTX) Financials
TGTX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 329.6 million | 169.1 million |
2023-09-30 | 331.1 million | 166.3 million |
2023-06-30 | 220.9 million | 180.4 million |
2023-03-31 | 197.4 million | 169.9 million |
TGTX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -13.2 million | 9.4 million |
2023-09-30 | 83.7 million | 9.2 million |
2023-06-30 | -42.0 million | 12.5 million |
2023-03-31 | -59.9 million | 6.8 million |
TGTX Net Income
No data available :(
TGTX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 217.5 million | - | 10.7 million |
2023-09-30 | 229.2 million | - | 11.0 million |
2023-06-30 | 144.9 million | 97.7 million | 11.3 million |
2023-03-31 | 139.7 million | 96.5 million | 11.6 million |
TGTX Shares Outstanding
TGTX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | - | 17.4 million | 34.0 million | -2.9 million |
2023-09-30 | - | 11.8 million | 35.7 million | -9.2 million |
2023-06-30 | - | 22.5 million | 36.4 million | - |
2023-03-31 | - | 14.3 million | 29.7 million | - |
TGTX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 44.0 million | 7.9 million |
2023-09-30 | 165.8 million | 3.5 million |
2023-06-30 | 16.1 million | 1.9 million |
2023-03-31 | 7.8 million | 857000 |
TGTX
Price: $16.52
52 week price:
Earnings Per Share: 0.09 USD
P/E Ratio: -80.79
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 2.7 million
Ebitda: -31.6 millionMarket Capitalization: 2.3 billion